ProCE Banner Activity

CE

Best Practices for the Implementation of Clinical Advances in HR-Positive/HER2-Negative Breast Cancer

Multimedia

Listen to the experts discuss current and emerging oral targeted therapies for advanced HR+/HER2- breast cancer, adverse event management, and strategies to promote adherence.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: May 03, 2022

Expiration: May 02, 2023

No longer available for credit.

Share

Faculty

Allison Butts

Allison Butts, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
Pharmacist Manager, Oncology
Program Director, PGY2 Hematology/Oncology Pharmacy Residency
Assistant Adjunct Professor
UK College of Pharmacy
Lexington, Kentucky

Kristina F. Byers

Kristina F. Byers, PharmD, BCOP

Clinical Pharmacy Specialist
Breast Oncology
Emory Winship Cancer Institute
Atlanta, Georgia

Provided by

Provided by ProCE, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Target Audience

The activity is intended for pharmacists, including clinical, managed care, and specialty pharmacists, who care for patients with hormone receptor–positive/HER2-negative early and advanced breast cancer, as well as other stakeholders in hematology/oncology practice.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss recent clinical evidence and the application of targeted oral therapies in personalized treatment planning for hormone receptor–positive/HER2-negative early and advanced breast cancer
  • Recognize and manage the adverse events associated with CDK4/6 and PI3K inhibitors, as well as novel SERD therapies
  • Integrate resources to engage patients in shared decision-making and medication adherence strategies for approved and investigational treatment options for hormone receptor–positive/HER2-negative early and advanced breast cancer

Disclosure

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Allison Butts, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
Pharmacist Manager, Oncology
Program Director, PGY2 Hematology/Oncology Pharmacy Residency
Assistant Adjunct Professor
UK College of Pharmacy
Lexington, Kentucky

Allison Butts, PharmD, BCOP, has disclosed that she has received consulting fees from AstraZeneca and BeyondSpring.

Kristina F. Byers, PharmD, BCOP

Clinical Pharmacy Specialist
Breast Oncology
Emory Winship Cancer Institute
Atlanta, Georgia

Kristina F. Byers, PharmD, BCOP, has disclosed that she has received consulting fees from Seagen and has been a speaker for Wellstat Therapeutics.

Staff Disclosure

Staff

Kelly Brandt, PharmD

Kelly Brandt, PharmD, BCOP, BCPS, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.

Jamie Sebaaly,

Director, Educational Strategy

Jamie Sebaaly has no relevant conflicts of interest to report.

Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN

Nurse Practitioner
Department of Urology
University of Virginia
Charlottesville, Virginia

Terran Sims, MSN, ACNP-C, CNN, COCN-C: consultant/advisor/speaker: Coloplast Corp.

Instructions for Credit

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-108-H01-P has been assigned to this home study, application-based activity. This activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 65% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Disclosure of Unlabeled Use

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 03, 2022, through May 02, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 03, 2022, through May 02, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve the knowledge, confidence, and competence of pharmacists in the management of patients with hormone receptor–positive/HER2-negative early and advanced breast cancer.